Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

• Hauptverfasser: Miriam Alonso-García (Verfasst von), Amparo Sánchez-Gastaldo (Verfasst von), Miguel A. Muñoz-Fuentes (Verfasst von), Sonia Molina-Pinelo (Verfasst von), Laura Boyero (Verfasst von), Johana Cristina Benedetti (Verfasst von), Reyes Bernabé-Caro (Verfasst von)
• Format: Buch
• Veröffentlicht: MDPI AG, 2022-04-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Nivolumab (anti-PD-1 antibody) and atezolizumab (anti-PD-L1 antibody) have shown superior survival outcomes and improved adverse effects compared to standard chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. However, the efficacy of both treatments has not been directly compared...